

POST-EDITED Machine Translation

from

RISING SUN COMMUNICATIONS LTD.

(Incorporating Rotha Fullford Leopold of Canberra, Australia)

The Nightingale Centre, 8 Balham Hill, London SW12 9EA


Tel: +44 (0)20 8673 0865 Fax: +44 (0)20 8675 0009

<http://www.risingsun.co.uk>

CLAIMS ONLY OF WO 00/66124

Limits of the Claims

1. A preventative or therapeutic agent of hepatopathy containing compound having following general formula (I), pharmacologically acceptable salt or derivative thereof.



{In the formula, either one of R¹ or R² denotes a heteroaryl group, or a heteroaryl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma; and the other denotes an aryl group, or an aryl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma,

R³ denotes a phenyl group, or a phenyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma, a group having formula -Q-R₄,

[Q denotes an arylene group, a heteroarylene group, an arylene group substituted with a group selected from the substituent group beta and the substituent group gamma, a heteroarylene group substituted with a group selected from the substituent group beta and the substituent group gamma, or a divalent group of 3 to 8-membered saturated heterocyclic ring containing at least one nitrogen atom,

R₄ denotes a group having general formula -WR₅, -OWR₅, -S(O)_mWR₅, -N(WR₅)R₆, -SO₂N(WR₅)R₆, -CON(WR₅)R₆, -COWR₅ or -PO(OR₇)(OR₈).

(In the formulae,


m denotes 0, 1 or 2,

W denotes an alkylene group, a lower alkenylene group, a cycloalkylene group, a cycloalkenylene group or a lower alkynylene group,


R5 denotes an azido group, a nitro group, a nitroso oxy group, a nitroxy group, a thiocyanate group, a group PO(OR7)(OR8), a group C(=NOR9) R10 or a group CON(OR9)R10,

R6, R9 and R10 are the same or different, and each denotes a hydrogen atom, an alkyl group of carbon number 1 to 15, an alkenyl group of carbon number 2 to 15, an alkynyl group of carbon number 2 to 15, an aryl group, an aralkyl group, a heteroaryl group, a heteroaryl alkyl group or a protecting group,

R7 and R8 are the same or different, and each denotes a hydrogen atom, an alkyl group of carbon number 1 to 15, an alkenyl group of carbon number 2 to 15, an alkynyl group of carbon number 2 to 15 or an aralkyl group respectively)], or a group having following general formula (II) or (III).



(II)



(III)

[In the formula, Het denotes a divalent group of 3 to 8-membered saturated heterocyclic ring containing at least one nitrogen atom,

R11 denotes a hydrogen atom, a lower alkyl group, an aralkyl group, a lower alkyl sulphonyl group, an aryl sulphonyl group, an aryl sulphonyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma, a carbamoyl group, a mono lower alkyl carbamoyl group, a di(lower alkyl) carbamoyl group, a sulphamoyl group, a mono lower alkyl amino sulphonyl group, a di(lower alkyl) amino sulphonyl group, or a protecting group of imino group,

A denotes a single bond, an oxygen atom, a sulphur atom, a carbonyl group, -SO-, -SO2-, -C(R17)(R18)- (wherein, R17 and R18 are the same or different, and denote a hydrogen atom, a hydroxy group, a halogen atom or a lower alkyl group), -N(R19)- (wherein, R19 denotes hydrogen atom or a lower alkyl group), or =C=NOR19 (wherein, R19 has the same aforesaid definition),

D denotes a single bond or -C(R20)(R21)- (wherein, R20 and R21 are the same or different, and denote a hydrogen atom, a hydroxy group, a halogen atom or a lower alkyl group),

R12 denotes halogen atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group or a halogeno lower alkoxy group,

R13, R14, R15 and R16 are the same or different, and denote hydrogen atom or a lower alkyl group,

K denotes an integer of 0 to 3 (when k is 2 or 3, the plurality of group R12 may be the same or different to each other),

m denotes 0, 1 or 2],

Z1 denotes oxygen atom, sulphur atom or >NR₂₂. (In the formula, R₂₂ denotes a hydrogen atom, an alkyl group of carbon number 1 to 15, an alkenyl group of carbon number 2 to 15, an alkynyl group of carbon number 2 to 15, an alkyl group of carbon number 1 to 15 substituted with 1-3 groups selected from the substituent group beta and the substituent group delta, an alkenyl group of carbon number 2 to 15 substituted with 1-3 groups selected from the substituent group beta and the substituent group delta, or an alkynyl group of carbon number 2 to 15 substituted with 1-3 groups selected from the substituent group beta and the substituent group delta.)

Z2 denotes a nitrogen atom or =C(R₂₃)- (wherein, R₂₃ denotes a hydrogen atom, an alkyl group of carbon number 1 to 15, an alkenyl group of carbon number 2 to 15, an alkynyl group of carbon number 2 to 15, an alkyl group of carbon number 1 to 15 substituted with 1-3 groups selected from the substituent group beta and the substituent group delta, an alkenyl group of carbon number 2 to 15 substituted with 1-3 groups selected from the substituent group beta and the substituent group delta, an alkynyl group of carbon number 2 to 15 substituted with 1-3 groups selected from the substituent group beta and the substituent group delta, a halogen atom or a nitro group.)}

[Substituent group alpha].

A lower alkyl sulphanyl group, a lower alkyl sulphonyl group, -SO₂NR_aR_b group (wherein, R_a and R_b are the same or different, and denote a hydrogen atom, an alkyl group of carbon number 1 to 15 or an aralkyl group), -NHCONR_cR_d group (wherein, R_c and R_d are the same or different, and denote a hydrogen atom, an alkyl group of carbon number 1 to 15 or an aralkyl group), a lower alkyl sulphonyl amino group.

[Substituent group beta].

A halogen atom, a cyano group, NR_eR_f (wherein, R_e and R_f are the same or different, and each denotes a hydrogen atom, an alkyl group of carbon number 1 to 15, a halogeno lower alkyl group

or an aralkyl group, or forms a heterocyclyl group containing at least one nitrogen atom together with the nitrogen atom bonded to them), ORe (wherein, Re has the same aforesaid definition), and SRe (wherein, Re has the same aforesaid definition).


[Substituent group gamma].

A lower alkyl group and a lower alkyl group substituted with 1-3 groups selected from aforesaid substituent group beta.

[Substituent group delta]

An aryl group, a heteroaryl group and a heterocyclyl group (these groups may be substituted with 1-3 groups selected from the substituent group beta and the substituent group gamma).

2. A preventative or therapeutic agent of hepatopathy in accordance with Claim 1, containing a compound having following general formula (I-A) or (I-B), pharmacologically acceptable salt or derivative thereof.



3. A preventative or therapeutic agent of hepatopathy in accordance with Claim 2, wherein the agent contains a compound having general formula (I-A), pharmacologically acceptable salt or derivative thereof.

4. A preventative or therapeutic agent of hepatopathy in accordance with Claim 3, wherein R¹ comprises a heteroaryl group or a heteroaryl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

5. A preventative or therapeutic agent of hepatopathy in accordance with Claim 3, wherein R¹ comprises pyridyl group, pyrimidinyl group, pyridyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma, or pyrimidinyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

6. A preventative or therapeutic agent of hepatopathy in accordance with Claim 3, wherein R1 comprises pyridyl group or pyridyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

7. A preventative or therapeutic agent of hepatopathy in accordance with Claim 3, wherein R1 comprises 4-pyridyl group or 4-pyridyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

8. A preventative or therapeutic agent of hepatopathy in accordance with Claim 3, wherein R1 comprises unsubstituted 4-pyridyl group.

9. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 3-8, wherein R2 comprises an aryl group or an aryl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

10. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 3-9, wherein R2 comprises phenyl group or phenyl group substituted with 1-3 groups selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

11. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 3-9, wherein R2 comprises phenyl group or phenyl group substituted with 1-3 groups selected from the following substituent group.

[Substituent group]

A halogen atom, a C1-C4 alkyl group, a C1-C4 halogeno alkyl group, a C1-C4 alkoxy group, a C1-C4 halogeno alkoxy group, a C1-C4 alkylthio group.

12. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 3-9, wherein R2 comprises phenyl group or phenyl group substituted with 1-3 groups selected from the following substituent group.

[Substituent group]

Fluorine atom, chlorine atom, difluoro methoxy group, trifluoromethyl group.

13. A preventative or therapeutic agent of hepatopathy in accordance with Claim 2, wherein the agent contains a compound having general formula (I-B), pharmacologically acceptable salt or derivative thereof.

14. A preventative or therapeutic agent of hepatopathy in accordance with Claim 13, wherein R1 comprises an aryl group or an aryl group substituted with 1-3 groups selected from the substituent group alpha.

15. A preventative or therapeutic agent of hepatopathy in accordance with Claim 13 or 14, wherein R2 comprises a heteroaryl group or a heteroaryl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

16. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-15, wherein R23 comprises hydrogen atom or a C1-C4 alkyl group

17. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-15, wherein R23 comprises hydrogen atom, methyl group or ethyl group.

18. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-17, wherein R3 comprises phenyl group or a phenyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

19. A preventative or therapeutic agent of hepatopathy in accordance with Claim 18, wherein R3 comprises a phenyl group substituted with a group selected from the substituent group alpha, the substituent group beta and the substituent group gamma.

20. A preventative or therapeutic agent of hepatopathy in accordance with Claim 18, wherein R3 comprises a phenyl group substituted with a group selected from the following substituent group.

[Substituent group]

A lower alkylthio group, a lower alkyl sulphanyl group, a lower alkyl sulphonyl group, -NReRf group (wherein, Re and Rf are the same or different, and denote a hydrogen atom, a lower alkyl group or an aralkyl group), -SO₂NRaRb group (wherein, Ra and Rb are the same or different, and denote a hydrogen atom, a lower alkyl group or an aralkyl group), a hydroxy group, a nitro group, a lower alkyl sulphonyl amino group.

21. A preventative or therapeutic agent of hepatopathy in accordance with Claim 18, wherein R3 comprises a phenyl group substituted with a group selected from the following substituent group.

[Substituent group]

A lower alkylthio group, a lower alkyl sulphanyl group, a lower alkyl sulphonyl group, -NReRf group (wherein, Re and Rf are the same or different, and denote a hydrogen atom, a lower alkyl group or an aralkyl group), -SO₂NRaRb group (wherein, Ra and Rb are the same or different, and denote a hydrogen atom, a lower alkyl group or an aralkyl group).

22. A preventative or therapeutic agent of hepatopathy in accordance with Claim 18, wherein R3 comprises 4-(lower alkylthio) phenyl, 4-(lower alkyl sulphanyl) phenyl or 4-(lower alkyl sulphonyl) phenyl.

23. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-17, wherein R3 comprises a group having general formula (II).

24. A preventative or therapeutic agent of hepatopathy in accordance with Claim 23, wherein Het comprises azetidiny, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl.

25. A preventative or therapeutic agent of hepatopathy in accordance with Claim 23, wherein Het comprises azetidiny, pyrrolidinyl, piperidyl or piperazinyl.

26. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 23-25, wherein R11 comprises a hydrogen atom, a lower alkyl group, an aralkyl group, a lower alkyl sulphonyl group, an aryl sulphonyl group, an aryl sulphonyl group substituted with a group selected from the substituent group alpha or a protecting group of imino group.

27. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 23-25, wherein R11 comprises a hydrogen atom, a lower alkyl group or a protecting group of imino group.

28. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-17, wherein R3 comprises a group having general formula (III).

29. A preventative or therapeutic agent of hepatopathy in accordance with Claim 28, wherein R12 comprises a halogen atom, a C1-C4 alkyl group, a C1-C4 halogeno alkyl group, a C1-C4 alkoxy group or a C1-C4 halogeno alkoxy group.

30. A preventative or therapeutic agent of hepatopathy in accordance with Claim 28, wherein R12 comprises fluorine atom, chlorine atom, methyl group, methoxy group or difluoro methoxy group.

31. A preventative or therapeutic agent of hepatopathy in accordance with Claim 28, wherein k comprises 0.

32. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 28-31, wherein R13, R14, R15 and R16 are the same or different and denote hydrogen atom or a C1-C4 alkyl group.

33. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 28-31, wherein R13, R14, R15 and R16 are the same or different and denote hydrogen atom or methyl group.

34. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 28-33, wherein A comprises a single bond, oxygen atom, carbonyl group, -SO-, -SO₂-, -C(R17)(R18)-, -N(R19)- or =C=NOR19.

35. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 28-33, wherein A comprises a single bond, oxygen atom, carbonyl group, -SO₂-, -C(R17)(R18)-, -N(R19)- or =C=NOR19 .

36. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 28-33, wherein A comprises a single bond, oxygen atom, carbonyl group, -C(R17)(R18)-, -N(R19)- or =C=NOR19.

37. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 28-33, wherein A comprises a single bond, oxygen atom, carbonyl group, -C(R17)(R18)- or =C=NOR19.

38. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 34-37, wherein R17 and R18 are the same or different and denote hydrogen atom, hydroxy group, a halogen atom or a C1-C4 alkyl group.

39. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 34-37, wherein R17 and R18 are the same or different and denote hydrogen atom, hydroxy group, fluorine atom, methyl group or ethyl group.

40. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 34-39, wherein R19 comprises hydrogen atom or a C1-C4 alkyl group.

41. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 34-39, wherein R19 comprises hydrogen atom, methyl group or ethyl group.

42. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-17, wherein R3 comprises a group having formula -Q-R4.

43. A preventative or therapeutic agent of hepatopathy in accordance with Claim 42, wherein Q comprises an arylene group, a heteroarylene group or an arylene group substituted with a group selected from the substituent group beta and the substituent group gamma.

44. A preventative or therapeutic agent of hepatopathy in accordance with Claim 42, wherein Q comprises an arylene group or an arylene group substituted with a group selected from the substituent group beta and the substituent group gamma.

45. A preventative or therapeutic agent of hepatopathy in accordance with Claim 42, wherein Q comprises 1,4-phenylene or 1,4-phenylene substituted with a group selected from the substituent group beta and the substituent group gamma.

46. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-45, wherein R4 comprises a group having general formula -WR5, -OWR5 or -S(O)mWR5.

47. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-45, wherein R4 comprises a group having general formula -S(O)mWR5.


48. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-45, wherein R4 comprises a group having general formula -S(O)mWR5, and m is 1 or 2.

49. A preventative or therapeutic agent of hepatopathy in accordance with Claim 42, wherein Q comprises a divalent 3 to 8-membered saturated heterocycle group containing at least one nitrogen atom.

50. A preventative or therapeutic agent of hepatopathy in accordance with Claim 42, wherein Q comprises azetidinediyl, pyrrolidinediyl, imidazolysinediyl, oxazolidinediyl, thiazolidinediyl, piperidinediyl, piperazinediyl, morpholinediyl or thiomorpholinediyl.

51. A preventative or therapeutic agent of hepatopathy in accordance with Claim 42, wherein Q comprises azetidinediyl, pyrrolidinediyl, piperidinediyl or piperazinediyl.

52. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 49-51, wherein -Q-R4 group comprises a group having the following general formula (IV).



{In the formula, cyclic group:

denotes a divalent 3 to 8-membered saturated heterocycle group containing at least one nitrogen atom in the definition of Q, R4a denotes a group having general formula -WR5, -S(O)mWR5, -SO2N(WR5)R6, -CON(WR5)R6, -COWR5 or -PO(OR7)(OR8) in the definition of R4.}

53. A preventative or therapeutic agent of hepatopathy in accordance with Claim 52, wherein R4a comprises a group having general formula -WR5, -S(O)mWR5 or -COWR5.

54. A preventative or therapeutic agent of hepatopathy in accordance with Claim 52, wherein R4a comprises a group having general formula -WR5 or -COWR5.

55. A preventative or therapeutic agent of hepatopathy in accordance with Claim 52, wherein R4a comprises a group having general formula -WR5.

56. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-55, wherein W comprises an alkylene group, a lower alkenylene group or a lower alkynylene group.

57. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-55, wherein W comprises an alkylene group.

58. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-55, wherein W comprises a straight chain or branched chain alkylene group of carbon number 1 to 4.

59. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-55, wherein W comprises a straight chain or branched chain alkylene group of carbon number 1 to 3.

60. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-55, wherein W comprises methylene, ethylene or trimethylene.

61. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-55, wherein W comprises methylene or ethylene.

62. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-61, wherein R5 comprises azido group, nitro group, thiocyanate group or PO(OR7)(OR8) group [in the formula, R7 and R8 have the same aforesaid meanings].

63. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 42-61, wherein R5 comprises azido group or nitro group.

64. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-63, wherein R22 comprises hydrogen atom, an alkyl group of carbon number 1 to 15 or an alkyl group of carbon number 1 to 15 substituted with 1-3 groups selected from the substituent group beta and the substituent group delta.

65. A preventative or therapeutic agent of hepatopathy in accordance with any one of Claims selected from Claims 1-63, wherein R22 comprises hydrogen atom.

66. A preventative or therapeutic agent of hepatopathy in accordance with Claim 1, wherein the agent contains a compound selected from the following compounds, pharmacologically acceptable salt or derivative thereof,

2-(4-fluorophenyl)-5-(1-oxothiochroman-6-yl)-3-(pyridin-4-yl)-1H-pyrrole,

2-(3,4-difluorophenyl)-5-(1-oxothiochroman-6-yl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(3-chlorophenyl)-5-(1-oxothiochroman-6-yl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-(4-methylsulphinylphenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-(4-methylsulphonylphenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-(piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole, or
2-(4-fluorophenyl)-5-(1-methylpiperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole.

67. A preventative or therapeutic agent of hepatopathy in accordance with Claim 1, wherein the agent contains a compound selected from the following compounds, pharmacologically acceptable salt or derivative thereof.

5-[4-(2-azido ethylsulphinyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[4-(3-nitropropylsulphinyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[4-(3-nitropropylsulphonyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[4-(3-nitroxypropylsulphinyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(2-diethylphosphonoethylsulphinyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(2-diethylphosphonoethylsulphonyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-3-(pyridin-4-yl)-5-[4-(2-thiocyanateethylsulphinyl) phenyl]-1H-pyrrole,
2-(4-fluorophenyl)-3-(pyridin-4-yl)-5-[4-(2-thiocyanateethylsulphonyl) phenyl]-1H-pyrrole,
5-[4-(3-azido propylsulphinyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(3-azido propylsulphonyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-3-(pyridin-4-yl)-5-[4-(3-thiocyanate propylsulphinyl) phenyl]-1H-pyrrole,
2-(4-fluorophenyl)-3-(pyridin-4-yl)-5-[4-(3-thiocyanate propylsulphonyl) phenyl]-1H-pyrrole,
5-[4-(2-azido ethylsulphonyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(azidomethyl sulphanyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(azidomethyl sulphonyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[1-(2-diethylphosphonoethyl) piperidin-4-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[1-(2-nitroethyl) piperidin-4-yl]-3-(pyridin-4-yl)-1H-pyrrole,
5-[1-(diethylphosphonomethyl) piperidin-4-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[1-(3-nitropropionyl) piperidin-4-yl]-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[1-(dimethylphosphoryl) piperidin-4-yl]-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[4-(4-nitrobutylsulphinyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole,
2-(3-chlorophenyl) -5-[4-(3-nitropropylsulphinyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole, or
2-(3,4-difluorophenyl)-5-[4-(3-nitropropylsulphinyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole.

68. A preventative or therapeutic agent of hepatopathy in accordance with Claim 1, wherein the agent contains a compound selected from the following compounds, pharmacologically acceptable salt or derivative thereof.

5-[4-(2-azido ethyl sulphanyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[4-(3-nitropropylsulphanyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[4-(3-nitropropylsulphonyl) phenyl]-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(3-azidopropylsulphanyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(3-azidopropylsulphonyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(2-azidoethylsulphonyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[4-(azidomethylsulphanyl) phenyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
5-[1-(2-diethylphosphonoethyl) piperidin-4-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole,
2-(4-fluorophenyl)-5-[1-(2-nitroethyl) piperidin-4-yl]-3-(pyridin-4-yl)-1H-pyrrole,
5-[1-(diethylphosphonomethyl) piperidin-4-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole, or 2-(4-fluorophenyl)-5-[1-(3-nitropropionyl) piperidin-4-yl]-3-(pyridin-4-yl)-1H-pyrrole.

Rising Sun Communications Ltd. Terms and Conditions

Rising Sun Communications Ltd. shall not in any circumstances be liable or responsible for the accuracy or completeness of any translation unless such an undertaking has been given and authorised by Rising Sun Communications Ltd. in writing beforehand. More particularly, Rising Sun Communications Ltd. shall not in any circumstances be liable for any direct, indirect, consequential or financial loss or loss of profit resulting directly or indirectly from the use of any translation or consultation services by the customer.